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Abstract
Background/Objectives: Translocated endotoxin derived from intestinal bacteria is a driver of systemic inflammation and
oxidative stress. Severe endotoxaemia is an underappreciated, but characteristic finding in haemodialysis (HD) patients, and
appears to be driven by acute repetitive dialysis induced circulatory stress. Resistance to erythropoietin (EPO) has been
identified as a predictor of mortality risk, and associated with inflammation and malnutrition. This study aims to explore the
potential link between previously unrecognised endotoxaemia and EPO Resistance Index (ERI) in HD patients.
Methodology/Principal Findings: 50 established HD patients were studied at a routine dialysis session. Data collection
included weight, BMI, ultrafiltration volume, weekly EPO dose, and blood sampling pre and post HD. ERI was calculated as
ratio of total weekly EPO dose to body weight (U/kg) to haemoglobin level (g/dL). Mean haemoglobin (Hb) was 11.361.3 g/
dL with a median EPO dose of 10,000 [IQR 7,500–20,000] u/wk and ERI of 13.7 [IQR 6.9–23.3] ((U/Kg)/(g/dL)). Mean pre-HD
serum ET levels were significantly elevated at 0.6960.30 EU/ml. Natural logarithm (Ln) of ERI correlated to predialysis ET
levels (r = 0.324, p = 0.03) with a trend towards association with hsCRP (r = 0.280, p = 0.07). Ln ERI correlated with
ultrafiltration volume, a driver of circulatory stress (r = 0.295, p = 0.046), previously identified to be associated with increased
intradialytic endotoxin translocation. Both serum ET and ultrafiltration volume corrected for body weight were
independently associated with Ln ERI in multivariable analysis.
Conclusions: This study suggests that endotoxaemia is a significant factor in setting levels of EPO requirement. It raises the
possibility that elevated EPO doses may in part merely be identifying patients subjected to significant circulatory stress and
suffering the myriad of negative biological consequences arising from sustained systemic exposure to endotoxin.
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Introduction
Anaemia commonly occurs in patients with chronic kidney
disease (CKD), as a result of insufficient production of erythro-
poietin (EPO) by the kidneys. Effective treatment of anaemia has
been possible since the introduction of recombinant Human
Erythropoetin therapy in 1986 [1].
Initial observational studies of EPO in CKD suggested a reduced
risk of mortality with increasing haemoglobin levels, associated
with improved quality of life [2,3,4]. However, several clinical
trials in recent years have raised significant concerns regarding the
optimum haemoglobin targets and erythropoietin stimulating
agent (ESA) doses [5,6,7]. The randomised trials of Normal
Haematocrit Cardiac Trial [8] and TREAT, comparing lower to
higher haemoglobin (Hb) targets on composite endpoints, have
demonstrated an increased risk of cardiovascular (CV) events.
These include stroke and vascular access thrombosis and
a potential increased risk of death and provide no clear signal
concerning improved patient quality of life.
There remains controversy over whether the poorer outcomes
are due to higher absolute levels of haemoglobin or elevated EPO
dose, particularly in those patients who fail to achieve target
haemoglobin [9]. Patients who do not achieve Hb targets despite
elevated doses of EPO, or who require higher doses to maintain
their Hb are considered to be Erythropoietin Resistant or
Hyporesponsive [10,11].
Resistance toEPO,previously identifiedasapredictorofmortality
risk [12], is widespread. Iron deficiency is recognised as a significant
factor affecting ESA response, and is usually treated alongside
erythropoietin replacement as part of co-ordinated anaemia man-
agement in the CKD population. Other important factors modulat-
ing the individual’s response and potentially increasing ESA re-
sistance include infection, hyperparathyroidism, inadequate dialysis,
malnutrition and chronic inflammation [13,14].
Despite attempts to identify and treat known risk factors, ESA
resistance cannot always be explained, suggesting that there may
be alternative causes driving the condition. The drivers of systemic
inflammation are often obscure. In order to more fully understand
the complex relationship between EPO dose, Hb, clinical
condition and the dialysis process itself, we identified circulating
endotoxin as a potential factor influencing EPO response.
Endotoxin (without sepsis) was initially proposed as a stimulus
for immune activation in the pro-inflammatory state of congestive
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heart failure (CHF) [15]. Endotoxin is released by bacterial cell
wall breakdown, within and beyond the gut lumen, from effective
host defence mechanisms and by autolysis. Endotoxin enters the
circulation via bacterial translocation, passage of intact bacteria
and macro-molecules such as endotoxin across the intestinal
barrier [16].
Exposure to endotoxin, a profoundly pro-inflammatory stimu-
lus, results in release of a wide variety of pro-inflammatory
cytokines, and has been implicated in a broad range of other
pathophysiological responses, including oxidative stress, endothe-
lial dysfunction and impaired circulatory autoregulation [17,18].
We have recently reported significant incremental endotoxaemia
with worsening renal function across the range of CKD, with
levels roughly tripling after initiation of dialysis [19]. In HD
patients the severity of endotoxaemia was associated with both the
drivers (ultrafiltration volume and rate) and the consequences
(dialysis induced myocardial injury) of dialysis induced circulatory
stress.
We hypothesised that there was a potential link between
endotoxaemia and EPO resistance in HD patients, and aimed to
describe the relative contribution of circulating endotoxin levels to
EPO resistance in HD patients.
Methods
Objectives
This study aims to explore the potential link between previously
unrecognised endotoxaemia and EPO resistance in HD patients.
Ethics Statement
Ethical approval for the study was granted by Derbyshire Local
Research Ethics Committee. Written informed consent was
received from all participants.
Participants
Fifty prevalent HD patients were recruited from a single
hospital-based haemodialysis unit. All patients were haemodia-
lysed thrice weekly via native arterio-venous fistulae. Exclusion
criteria comprised; change in target weight in the preceding six
weeks, clinical evidence of blood loss, active infection or
malignancy, bone marrow disease or haemoglobinopathy, or
pre-existing severe LV systolic dysfunction (NYHA IV).
Methodology: Description of Procedures or
Investigations Undertaken
Haemodialysis details. Dialysis was performed using Hos-
pal Integra monitors (Hospal, Mirandola, Italy). Dialysate fluid
contained sodium, 138 mmol/L; potassium, 1 mmol/L; calcium
1.25 mmol/L; magnesium, 0.5 mmol/L; bicarbonate, 32 mmol/
L; glucose, 5.6 mmol/L; and acetate, 3 mmol/L. Dual pass water
treatment was used with undetectable levels of endotoxin
throughout study duration.
All studies were conducted after a 2 day interdialytic period.
Anticoagulation was with unfractionated heparin. Dialysate flow
was 500 mL/min, and dialysate temperature was set at 37uC. Net
fluid removal was set on an individual basis according to ideal dry
weight. Patients were permitted to eat during HD if this was their
usual preference.
Ultrafiltration rate. The rate of volume removal at dialysis,
expressed in ml/h/kg BW, measured by the weight change per
duration of HD treatment using the post HD weight as
denominator.
Data collection. The following basic demographic informa-
tion was obtained: age (years), sex, dialytic vintage (months),
cardiovascular comorbidities, diabetes mellitus, body weight (BW;
kg), body mass index (BMI; kg/m2). The following factors were
collected during the dialysis session: interdialytic weight gain
(IDWG, kg), ultrafiltration volume (l), ultrafiltration rate (UFR:
ml/h/kg body weight), pre-HD systolic and diastolic blood
pressure, mean arterial blood pressure (MAP; mmHg), dialysis
dose (Kt/V).
Erythropoietin dose. In order to normalize the amount of
EPO required depending on the severity of anaemia, we
calculated an EPO resistance (responsiveness) index (ERI), as
described in previous studies [20], defined as the weekly EPO dose
divided by Hb level (g/dl). Both the EPO dose and ERI were
divided by target body weight to indicate the required EPO dose
per kilogram of dry body weight.
Blood samples. All blood samples were taken before and
after a dialysis session with rapid separation of serum and storage
at 285uC before endotoxin measurement. Patients were not fasted
prior to blood sampling. Haemoglobin (Hb), ferritin, reticulocytes,
serum sodium, potassium, urea, creatinine, albumin, corrected
calcium, albumin, and intact parathyroid hormone (PTH) were
analyzed using standard autoanalyzer techniques (Roche diag-
nostics modular IIPH). Commercially available enzyme-linked
immunosorbent assay (ELISA) kits (DRG instruments, Germany)
were used to assess high-sensitivity C-reactive protein (hsCRP) and
Interleukin-6 (IL-6), according to the manufacturer’s protocol.
Circulating endotoxin level measurement. The method
of lipopolysaccharide (LPS) quantification has been described
previously [21]. Briefly, serum samples were diluted to 20% with
endotoxin-free water and then heated to 70uC for 10 minutes to
inactivate plasma proteins. Serum LPS was then quantified with
a commercially available Limulus Amebocyte assay (Cambrex,
Verviers, Belgium), according to the manufacturer’s protocol. The
detection limit of this assay was 0.01 EU/ml. Samples with LPS
level below the detection limit were taken as 0.01 EU/ml. All
samples were run in duplicate and background subtracted.
Statistical analysis. Results are presented as mean 6
standard deviation (SD) or the median and interquartile range
(IQR) unless otherwise stated. All data were tested for normality.
Categorical data were compared using Chi-square test, continuous
data using paired or unpaired Students t-test or one-way ANOVA
with Tukey’s correction as appropriate. Correlation between
continuous variables was examined by Pearson’s or Spearman’s
rank correlation coefficient. Factors associated with ERI/circulat-
ing endotoxin levels were further explored by a multivariable
linear regression model. Analysis was performed using SPSS v16.0
(SPSS Inc, Chicago, IL). P value of less than 0.05 was considered
significant. All probabilities were two-tailed.
Results
The patient characteristics and blood results are summarized in
Table 1. Mean Hb was 11.361.3 g/dL with a median weekly
EPO dose 169 IU/wk/kg [IQR 85–257]. EPO Resistance Index
for the whole population was 13.7 IU/kg/wk/gm per dl [IQR
6.9–23.9]. Mean pre-HD serum endotoxin levels were appreciably
elevated at 0.6960.30 EU/ml, significantly higher than those of
non-CKD patients (0.0460.01 EU/ml, p,0.001) [22].
Predialysis endotoxin levels correlated to both EPO dose and
natural logarithm (Ln) of ERI (r = 0.318, p= 0.03 and r = 0.324,
p = 0.03 respectively). EPO dose and Ln ERI demonstrated
a stronger relationship with ET than with traditional markers of
inflammation, including high sensitivity C-Reactive Protein
(hsCRP), Interleukin-6 (IL-6) and albumin. Endotoxin demon-
strated a trend towards correlation with haemodynamic instability,
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assessed by maximum drop in systolic blood pressure over the HD
treatment (r =20.270, p = 0.063), as did ultrafiltration volume
(r =20.270, p = 0.058). Endotoxin levels were not significantly
affected by the presence of diabetes mellitus (p = 0.61) or aspirin
use (p = 0.56).
Ln ERI correlated significantly with ultrafiltration (UF) volume
(r = 0.332, p = 0.026), a known driver of circulatory stress pre-
viously identified to be associated with increased intradialytic
endotoxin translocation. Adjusting UF volume for body weight (L/
kg), further strengthened this relationship (r = 0.419, p = 0.004). Ln
ERI demonstrated a trend towards correlation with hsCRP
(r = 0.281, p= 0.075) and inversely with BMI (r =20.259,
p = 0.082).
Ln ERI was not significantly affected by the presence of
cardiovascular comorbidities (p = 0.28), diabetes mellitus
(p = 0.78), or RAAS blockade (p = 0.41). EPO dose and Ln ERI
did not demonstrate significant correlations with other parameters
previously identified as linked to erythropoietin resistance, in-
cluding ferritin, parathyroid hormone levels, ktV and serum
albumin. This patient group were characterised by being well
dialysed, iron replete with well controlled hyperparathyroidism.
Univariable analysis is summarised in Table 2.
Multivariable analysis of factors contributing to EPO resistance
revealed that serum endotoxin and ultrafiltration volume cor-
rected for weight were independent variables associated with the
natural logarithm of EPO resistance index in models adjusted for
age, albumin, ferritin, PTH and Kt/V (see Table 3). In stepwise
linear regression, the model predicting ln ERI comprised
ultrafiltration volume corrected for body weight (b=0.472,
p = 0.001) and hsCRP (b=0.301, p = 0.033) with a model fit of
R2 = 0.297 (Adjusted R2= 0.260).
Discussion
In this study, we demonstrated for the first time endotoxin as an
independent determinant of EPO resistance. Significant endotox-
aemia has been identified and described in the severe CKD and
dialysis population [19,23] and these data confirm previous
findings. Endotoxin levels seen in HD patients are extremely
high, comparable with those reported in severe liver disease [24],
post gut irradiation [25] and in severe decompensated congestive
heart failure (CHF) [15]. Previous work in patients with acute
heart failure showed ET to be systemically elevated, with higher
levels in the hepatic vein compared to the left ventricle [26],
identifying the gut as the source of ET. In CHF, bowel oedema
and hypoperfusion have been identified as the two main factors
influencing bowel wall permeability [27], and therefore ET
translocation.
Factors involved in EPO resistance that can be modulated
include iron deficiency, hyperparathyroidism, inadequate dialysis
and malnutrition. Chronic inflammation, a common finding in
CKD and dialysis patients, is strongly associated with EPO
resistance [20]. Elevated circulating pro-inflammatory cytokines
(PIC) including hsCRP, IL-6, and TNF-a demonstrate significant
correlation with increasing levels of EPO hyporesponsiveness in
Table 1. Patient demographics, clinical characteristics and
laboratory parameter results.
Parameter Results
Age (yrs) 62.2614.7
Gender (Male : Female) 36:14
Dialysis vintage (months; median [IQR]) 38 [18,70]
Ethnicity (%)
Caucasian 94
Asian 6
Cause of end-stage renal disease (%)
Diabetic nephropathy 28
Glomerular disease 22
Adult polycystic kidney disease 12
Urological 10
Multiple myeloma 4
Tubulointerstitial nephritis 4
Unknown 10
Other 10
Diabetes Mellitus (%) 38
Cardiovascular Comorbidities (%) 42
EPO dose (IU/week) 10,000 [7,500–20,000]
ERI (IU/kg/wk/g/dl) 13.7 [6.9–23.9]
Weight (kg) 78.9617
Body Mass Index (kg/m2) 2765.5
Kt/V urea 1.360.2
Ultrafiltration volume (Litres) 1.9760.76
Predialysis systolic BP (mmHg) 144622
Predialysis diastolic BP (mmHg) 76614
Haemoglobin (g/dl) 11.361.3 g
Haematocrit (%) 3664
Ferritin (ug/L) 307 [213–454]
Phosphate (mmol/L) 1.4560.39
Adjusted Calcium (mmol/L) 2.460.13
Albumin (g/L) 3663.8
Parathyroid Hormone (ng/L) 240 [96–342]
hsCRP (mg/L) 1.32 [0.82–2.23]
IL-6 (pg/ml) 0.099 [0.086–0.115]
Data are mean6SD or median [IQR].
ERI, EPO Resistance Index, BP, Blood pressure; hsCRP, high sensitivity C Reactive
Protein; IL-6, Interleukin 6.
doi:10.1371/journal.pone.0040209.t001
Table 2. Univariable associates of clinical and laboratory
parameters with natural logarithm of EPO Resistance Index.
Parameter R value P value
Serum endotoxin (EU/ml) 0.311 0.04
Ultrafiltration volume (L) 0.332 0.026
UF volume/body weight (L/kg) 0.470 0.001
Age (years) 0.057 0.711
Body Mass Index (kg/m2) 20.259 0.082
Ferritin (ug/L) 0.08 0.6
Parathyroid Hormone (ng/L) 0.19 0.25
Kt/Vurea 20.18 0.26
Albumin (g/L) 20.70 0.67
hsCRP (mg/L) 0.280 0.07
IL-6 (ng/ml) 0.16 0.32
UF, ultrafiltration; hsCRP, high sensitivity C Reactive Protein; IL-6, Interleukin 6.
doi:10.1371/journal.pone.0040209.t002
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the dialysis population [20,28]. A variety of factors have been
postulated as drivers of chronic inflammation in CKD, and
endotoxin is a potential unifying feature of the interlinked
malnutrition, inflammation and CV disease state in dialysis
patients.
In this patient group, hsCRP demonstrated a trend towards
correlation with ln ERI. This may be attributable to the narrow
range of hsCRP values in this patient group, differences in
immunoreactivity or insufficient patient numbers to achieve
significance. Tachyphylactic response to endotoxin has been
previously described, where further contact with, or incremental
exposure to endotoxin can result in a diminishing physiological
response. The use of native AV fistulae, ultrapure dialysis solution
and absence of active intercurrent clinical events such as infection
or vascular access issues will affect levels of inflammatory markers
in the patient group. The complexities of the uraemic environ-
ment, dialysis related and patient specific factors will contribute
towards variability in the individual’s inflammatory response.
Exposure to ET results in release of a wide variety of PICs and
binding via CD14 to systemic immune competent cells. Mechan-
isms of cytokine related anaemia include reduction of renal EPO
production, inhibition of the proliferation and differentiation of
erythroid progenitor cells in the bone marrow, impaired iron
absorption and reduced iron delivery [29,30]. In animal models,
induced endotoxaemia has been demonstrated to suppress ESA
ability to stimulate erythropoiesis [31].
Endotoxin contamination of dialysis water has long been
recognised as a cause of low grade inflammatory response and
CV instability during dialysis [32]. Endotoxin exposure in sub-
optimally prepared dialysis water has been linked to increased
EPO resistance [33], whereas transition to ultrapure dialysate can
reduce systemic inflammation and EPO dose requirements [34].
Circulating serum ET levels of 0.69 EU/ml in our patient group
were greatly elevated, above even the maximum current permitted
levels of endotoxin in dialysate fluid of 0.25 EU/ml. Dialysis water
in this study had undetectable levels of endotoxin during the study
period, following dual pass water treatment. Circulating ET in
these patients therefore originates from an alternate source,
namely the gastrointestinal tract.
HD itself appears to be responsible for increasing exposure to
translocated intestinal endotoxin, as evidenced by a large differ-
ence between patients with very severe CKD stage 5, but not yet
started on dialysis, and those receiving dialysis [19]. HD, in
combination with ultrafiltration, results in significant systemic
haemodynamic perturbation and clinically significant reduction of
regional perfusion in critical organs such as the heart and brain
[35]. HD is well described as being capable of inducing recurrent
cardiac ischaemic injury, associated with long term myocardial
damage and increased mortality [36]. Previous work has
demonstrated significant correlation between endotoxin and
severity of HD-induced cardiac stunning and relative hypotension
[19].
Patients on long-term maintenance haemodialysis have evi-
dence of mucosal ischaemia [37] and ultrafiltration causes
a reduction in splanchnic blood volume [38] despite preserved
blood pressure [39]. Mesenteric ischaemia results in disrupted gut
mucosal structure and function, with increased gut permeability
[40]. HD may result in recurrent regional hypoperfusion,
particularly in the splanchnic vasculature. This can result in
subclinical mesenteric ischaemia and injury, leading to altered
membrane permeability and increased translocation of endotoxin.
Increasing ERI is associated with higher volumes of fluid
removal during dialysis, and unsurprisingly this association
increases when UF volume is corrected for body weight. Previous
work has demonstrated significant correlation between endotox-
aemia and dialysis induced haemodynamic stress, including
severity of HD-induced cardiac stunning, markers of cardiac
injury and relative hypotension [19]. Ultrafiltration volume is
potentially a driver of both myocardial and splanchnic hypoperfu-
sion, with end-organ injury resulting in system specific short-term
injury and long-term damage, as well as a generalised in-
flammatory response.
Adding endotoxin into a simple linear regression model for ln
ERI containing UF volume/weight and hsCRP strengthened the
R2 of the model (0.307), but both ET and hsCRP were no longer
independent predictors within it. This is not unexpected, given the
underlying pathophysiological processes linking these factors. The
relationships between potential causes and consequences of
endotoxaemia, may, in turn, influence EPO resistance. Multivari-
able analysis confirmed the independent association of serum
endotoxin and of ultrafiltration volume corrected for weight with
the natural logarithm of EPO resistance index, when adjusted for
factors previously identified as influencing the response to EPO.
In terms of potential intervention, extended dialysis schedules
are associated with marked reductions in UF requirements and
intradialytic hypotension, lessening the haemodynamic insult [19],
as well as improving Hb and lowering EPO requirements [41].
This study has potential limitations. Although this observational
study was able to demonstrate a relationship between endotox-
aemia and EPO resistance in HD patients, the sample size is
inadequate to fully resolve factors relating to the degree of
endotoxaemia or EPO hypo-responsiveness. Patients were not
prevented from eating during HD, which could potentially
influence gut perfusion and permeability, however the relatively
high fibre and low fat meals provided are likely to have only
limited impact on ET translocation. Areas of further work include
longitudinal studies on ET, inflammatory response and EPO
requirements, exploration of the effects of reduced endotoxin
exposure on EPO requirements, and comparison of ET and ERI
between different dialysis modalities.
Summary
This study suggests that endotoxaemia, either by direct
interaction, or through its well documented effects on systemic
inflammation, is a significant and potentially dominant factor in
setting levels of EPO requirement. It raises the possibility that
elevated EPO doses may in part merely be identifying patients
subjected to significant haemodynamic perturbation, and suffering
the myriad of negative biological consequences arising from
sustained systemic exposure to endotoxin.
A greater understanding of the mechanism and factors
influencing endotoxin translocation in the dialysis population is
required. In addition, turning our attention to the dialysis
procedure itself may yield additional benefits, both in terms of
Table 3. Multivariable analysis model for natural logarithm of
EPO Resistance Index (adjusted for age, albumin, ferritin, PTH
and Kt/V).
R2
Adjusted
R2 Beta SE P value
UF volume/body
weight (L/kg)
0.325 0.202 40.3 12.2 0.002
Serum endotoxin
(EU/ml)
0.214 0.071 1.06 0.49 0.037
doi:10.1371/journal.pone.0040209.t003
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EPO requirements, but also alleviating the haemodynamic impact
of HD to improve long-term patient outcomes.
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